medigraphic.com
ISSN 1561-3070 (Digital)

2013, Número 1

<< Anterior Siguiente >>

Rev Cub Oftal 2013; 26 (1)


Tratamiento de la neovascularización coroidea miópica

Lapido PSI, González DRE, Rodríguez RV, González AY, Baldoquín RW, Rúa MR

Idioma: Español
Referencias bibliográficas: 71
Paginas: 129-143
Archivo PDF: 78.96 Kb.


RESUMEN

Se realizó una revisión sobre el tratamiento de la neovascularización coroidea en la miopía degenerativa. Se consultaron fundamentalmente artículos científicos de revistas publicados e indexados en las bases de datos PubMED y Cochrane, así como textos básicos que abordan este tema. No se encontraron certezas del beneficio de la fotocoagulación con láser de las lesiones neovasculares en esta entidad, mientras que la terapia fotodinámica parece brindar estabilidad de la lesión y mejoría visual, al menos a los 3 años de seguimiento. El uso de antiangiogénicos intravítreos tiene los mejores resultados en la actualidad respecto a la inactivación de la lesión y la recuperación visual pero no hay ensayos clínicos controlados que avalen su beneficio a largo plazo. Otras opciones de tratamiento se encuentran en investigación y desarrollo. No se ha concebido el protocolo ideal para tratar las membranas neovasculares miópicas.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Soubrane G, Coscas GJ. Choroidal neovascular membrane in degenerative myopia. In: Ryan SJ, Schachat AP, editors. Retina. 4ta ed. Philadelphia: Elsevier-Mosby; 2006. p. 1115-31.

  2. Ryan SJ, Hinton DR, Murata T. Choroidal neovascularization. In: Ryan SJ, Schachat AP, editors. Retina. 4ta ed. Philadelphia: Elsevier-Mosby; 2006. p. 991-1010.

  3. Falk T, Congrove NR, Zhang S, McCourt AD, Sherman SJ, McKay BS. PEDF and VEGF-A output from human retinal pigment epithelial cells grown on novel microcarriers. J Biomed Biotechnol. 2012 [cited 2012 Jun 15 ]:278-932. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3323925 /pdf/JBB2012-278932.pdf

  4. Yoshida T, Ohno-Matsui K, Yasuzumi K, Kojima A, Shimada N, Futagam iS. Myopic choroidal neovascularization: a 10-year follow-up. Ophthalmology. 2003;110(7):1297-305.

  5. Curtin BJ, Karlin DB. Axial length measurement and fundus changes of the myopic eye. Am J Ophthalmol. 1971;71Pt 1:42-50.

  6. Soubrane G. Choroidal neovascularization in pathologic myopia: recent developments in diagnosis and treatment. Surv Ophthalmol. 2008;53(2):121-38.

  7. Cohen SY, Laroche A. Etiology of choroidal neovascularization in young patients. Ophthalmol. 1996;103(8):1241-4.

  8. Virgili G, Menchini F. Fotocoagulación con láser para la neovascularización coroidal de la miopía patológica (Revisión Cochrane traducida). La Biblioteca Cochrane Plus. Oxford: Update Software Ltd; 2008.

  9. Brancato R, Menchini U, Pece A, Capoferri C, Avanza P, Radrizzani E. Dye laser photocoagulation of macular subretinal neovascularization in pathological myopia. A randomized study of three different wavelengths. Ophthalmol. 1988;11(4):235-8.

  10. Fardeau C, Soubrane G, Coscas G. Laser treatment of choroidal neovascularization in degenerative myopia. Bulletin des Societes d'Ophtalmologie de France. 1992;92(3):239-42.

  11. Secretan M, Soubrane G, Kuhn D. Long-term follow-up of choroidal neovascularization in pathologic myopia: natural history compared to laser treatment. Eur J Ophthalmol. 1997;7(4):307- 16.

  12. Verteporfin in Photodynamic Therapy Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial VIP report no. 1. Ophthalmol. 2001;108(5):841-52.

  13. Blinder KJ, Blumenkranz MS, Bressler NM, Bressler SB, Donato G, Lewis H. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial VIP report no. 3. Ophthalmol. 2003;110(4):667-73.

  14. Verteporfin in Photodynamic Therapy (VIP) Study Group. Verteporfin in Photodynamic Therapy: Report No. 5. Ophthalmol. 2004;111(11):2144.

  15. Chen YS, Lin JY, Tseng SY, Yow SG, Hsu WJ, Tsai SC. Photodynamic therapy for Taiwanese patients with pathologic myopia: a 2-year follow-up. Retina. 2007;27(7):83945.

  16. Hayashi K, Ohno-Matsui K, Teramukai S. Photodynamic therapy with verteporfin for choroidal neovascularization of pathologic myopia in Japanese patients: comparison with nontreated controls. Am J Ophthalmol. 2008;145(3):518-26.

  17. Montero JA, Ruiz-Moreno JM. Verteporfin photodynamic therapy in highly myopic subfoveal choroidal neovascularisation. Br J Ophthalmol. 2003;87(2):173-6.

  18. Hussain N, Khanna R, Das T, Narayanan R, Tunji Sunday O, Gaurav Bansal A, et al. Two years follow-up outcome of verteporfin therapy for subfoveal choroidal neovascularization in pathologic myopia in Indian eyes. Indian J Ophthalmol. 2008;56(6):465-8.

  19. Giansanti F, Virgili G, Donati MC, Giuntoli M, Pieretti G, Abbruzzese G, et al. Long-term results of photodynamic therapy for subfoveal choroidal neovascularization with pathologyc myopia. Retina. 2012;32(8):1547-52.

  20. Pece A, Vadalà M, Isola V, Matranga D. Photodynamic therapy with verteporfin for juxtafoveal choroidal neovascularization in pathologic myopia: a long-term follow-up study. Am J Ophthalmol. 2007;143(3):449-54.

  21. Virgili G, Varano M, Giacomelli G. Photodynamic therapy for nonsubfoveal choroidal neovascularization in 100 eyes with pathologic myopia. Am J Ophthalmol. 2007;143(1):77-82.

  22. Potter MJ, Szabo SM, Ho T. Combined photodynamic therapy and intravitreal triamcinolone for the treatment of myopic choroidal neovascularization in a 13-year-old girl. Graefes Arch Clin Exp Ophthalmol. 2006;244(5):639-41.

  23. Marticorena J, Gomez-Ulla F, Fernandez M, Pazos B, Rodriguez-Cid MJ, Sanchez-Salorio M. Combined photodynamic therapy and intravitreal triamcinolone acetonide for the treatment of myopic subfoveal choroidal neovascularisation. Am J Ophthalmol. 2006;142(2):335-7.

  24. Chan WM, Lai TY, Wong AL, Liu DT, Lam DS. Combined photodynamic therapy and triamcinolone injection for the treatment of choroidal neovascularisation secondary to pathological myopia: a pilot study. Br J Ophthalmol. 2007;91(2):131-3.

  25. Bennett MD, Yee W. Pegaptanib for myopic choroidal neovascularization in a young patient. Graefes Arch Clin Exp Ophthalmol. 2007;245(6):903-5.

  26. Avetisov SE, Budznskaia SA, Likhvantseva VG, Gurova IV, Loshchenov VB, Shevchik SA, et al. The first results of phase IIA of clinical studies of photodynamic therapy for subfoveal neovascular membranes with photosense. Vestnik oftalmologii. 2005;121(5):6-9.

  27. Parmeggiani F, Gemmati D, Costagliola C, Semeraro F, D'Angelo S, Perri P, et al. Impact of coagulation-balance gene predictors on efficacy of photodynamic therapy for choroidal neovascularization in pathologic myopia. Ophthalmol. 2010;117(3):517-23.

  28. Castro R, Rivera I, Blom HJ. Homocysteine metabolism, hyperhomocysteinaemia and vascular disease: an overview. J Inherit Metab Dis. 2006;29(1):3-20.

  29. Costagliola C, Campa C, Incorvaia C. Verteporfin photodynamic therapy for subfoveal choroidal neovascularization in pathologic myopia: a 12-month retrospective review. Eur J Ophthalmol. 2008;18(6):955-9.

  30. Kaiser PK. Antivascular endothelial growth factor agents and their development: therapeutic implications in ocular diseases. Am J Ophthalmol. 2006;142(4):660-8.

  31. Peters S, Julien S, Heiduschka P, Grisanti S, Ziemssen F, Adler M, et al. Antipermeability and antiproliferative efects of standard and frozen bevacizumab on choroidal endothelial cells. Br J Ophthalmol. 2007;91(6):827-31.

  32. Lai TY. Anti-vascular endothelial growth factor therapy for myopic choroidal neovascularization: do we need more evidence? Retina. 2012;32(8):1443-5.

  33. Figueroa M, Noval S, Contreras I. Revisión actualizada de las terapias antiangiogénicas. Studium Ophthalmologicum. 2006;24(3):185-99.

  34. Clinical Trial Update. Wet AMD. Retinal Physician. 2008;5(7):71-85.

  35. Nagpal M, Nagpal K, Nagpal P. A comparative debate on the various anti-vascular endothelial growth factor drugs: Pegaptanib sodium (Macugen), ranibizumab (Lucentis) and bevacizumab (Avastin). Indian J Ophthalmol. 2007;55(6):437-9.

  36. Rinaldi M, Chiosi F, Dell'omo R, Romano MR, Parmeggiani F, Semeraro F, et al. Intravitreal pegaptanib sodium (Macugen) for treatment of myopic choroidal neovascularization: a morphologic and functional study. Epub ahead of print. Retina. 2012;0(0):1-6.

  37. Bennett MD, Yee W. Pegaptanib for myopic choroidal neovascularization in a young patient. Graefes Arch Clin Exp Ophthalmol. 2007;245(6):903-5.

  38. Raftery J, Clegg A, Jones J. Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness. Br J Ophthalmol. 2007;91(9):1244-6.

  39. Hussain N, Ghanekar Y, Kaur I. The future implications and indications of anti-vascular endothelial growth factor therapy in ophthalmic practice. Indian J Ophthalmol. 2007;55(6):445-50.

  40. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, et al. ANCHOR Study Group. Ranibizumab versus Verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1432-44.

  41. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419-31.

  42. Scott IU, Bressler NM, Bressler SB, Browning DJ, Chan CK, Danis RP, et al. Agreement between clinician and reading center gradings of diabetic retinopathy severity level at baseline in a phase 2 study of intravitreal bevacizumab for diabetic macular edema. Retina. 2008;28(1):36-40.

  43. Ruiz-Moreno JM, Montero JA, Gomez-Ulla F, Ares S. Intravitreal bevacizumab to treat subfoveal choroidal neovascularisation in highly myopic eyes: 1-year outcome. Br J Ophthalmol. 2009;93(4):448-51.

  44. Lai TY, Chan WM, Liu DT, Lam DS. Intravitreal ranibizumab for the primary treatment of choroidal neovascularization secondary to pathologic myopia. Retina. 2009;29(6):750-6.

  45. Chan WM, Lai TY, Liu DT, Lam DS. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularisation: 1-year results of a prospective pilot study. Br J Ophthalmol. 2009;93(2):150-4.

  46. Gharbiya M, Allievi F, Mazzeo L, Gabrieli CB. Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12-month results. Am J Ophthalmol. 2009;147(1):84-93.

  47. Battaglia Parodi M, Iacono P, Bandello F. Antivascular endothelial growth factor for choroidal neovascularization in pathologic myopia. Dev Ophthalmol. 2012;46(8):73-83.

  48. Gharbiya M, Giustolisi R, Allievi F, Fantozzi N, Mazzeo L, Scavella V, et al. choroidal neovascularization in pathologic myopia: Intravitreal ranibizumab versus bevacizumab a randomized controlled trial. Am J Ophthalmol. 2010;149(3):458-64.

  49. Dave V, Narayanan R. Choroidal neovascularization in pathologic myopia [Correspondence]. Am J Ophthalmol. 2010;150(5):752-3.

  50. Iacono P, Parodi MB, Papayannis A, Kontadakis S, Sheth S, Cascavilla ML, et al. Intravitreal ranibizumab versus bevacizumab for treatment of myopic choroidal neovascularization. Retina. 2012;32(8):1539-46.

  51. Vadala M, Pece A, Cipolla S, Monteleone C, Fasolino G, Casuccio A, et al. Is ranibizumab effective in stopping the loss of vision for choroidal neovascularisation in pathologic myopia? A long-term follow-up study. Br J Ophthalmol. 2011;95(5):657-61.

  52. Arias L, Planas N, Prades S, Caminal JM, Rubio M, Pujol O, et al. Intravitreal bevacizumab (Avastin) for choroidal neovascularisation secondary to pathological myopia: 6-month results. Br J Ophthalmol. 2008;92(8):1035-9.

  53. Voykov B, Gelisken F, Inhoffen W, Voelker M, Bartz-Schmidt KU, Ziemssen F. Bevacizumab for choroidal neovascularization secondary to pathologic myopia: Is there a decline of the treatment efficacy after 2 years? Graefes Arch Clin Exp Ophthalmol. 2010;248(4):543-50.

  54. Battaglia Parodi M, Iacono P, Papayannis A, Sheth S, Bandello F. Laser photocoagulation, photodynamic therapy, and intravitreal bevacizumab for the treatment of juxtafoveal choroidal neovascularization secondary to pathologic myopia. Arch Ophthalmol. 2010;128(4):437-42.

  55. Yoon JU, Byun YJ, Koh HJ. Intravitreal anti-VEGF versus photodynamic therapy for treatment of myopic choroidal neovascularization. Retina. 2010;30(3):418-24.

  56. Baba T, Kubota-Taniai M, Kitahashi M, Okada K, Mitamura Y, Yamamoto S. Two-year comparison of photodynamic therapy and intravitreal bevacizumab for treatment of myopic choroidal neovascularisation. Br J Ophthalmol. 2010;94(7):864-70.

  57. Ruiz-Moreno JM, Montero JA. Intravitreal bevacizumab to treat myopic choroidal neovascularization: 2-year outcome. Graefes Arch Clin Exp Ophthalmol. 2010;248(7):937-41.

  58. Scupola A, Tiberti AC, Sasso P, Savastano MC, Mastrocola A, Marangoni D, et al. Macular functional changes evaluated with MP-1 microperimetry after intravitreal bevacizumab for subfoveal myopic choroidal neovascularization. Retina. 2010;30(5):739-47.

  59. Wu TT, Kung YH. The 12-month outcome of three consecutive monthly intravitreal injections of ranibizumab for myopic choroidal neovascularization. J Ocul Pharmacol Ther. 2012;28(2):129-33.

  60. Nguyen QD, Shah S, Tatlipinar S, Do DV, Anden EV, Campochiaro PA. Bevacizumab suppresses choroidal neovascularisation caused by pathological myopia. Br J Ophthalmol. 2005;89(10): 1368-70.

  61. Mordenti J, Cuthbertson RA, Ferrara N. Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol. 1999;27(5):536-44.

  62. Wang J, Kang Z. Summary of prognostic factors for choroidal neovascularization due to pathological myopia treated by intravitreal bevacizumab injection. Graefes Arch Clin Exp Ophthalmol. 2012;250(12):1717-23.

  63. Matsuo M, Honda S, Matsumiya W, Kusuhara S, Tsukahara Y, Negi A. Comparison between anti-vascular endothelial growth factor therapy and photodynamic therapy for myopic choroidal neovascularization. Eur J Ophthalmol. 2012;22(2):210-5.

  64. Hayashi K, Ohno-Matsui K, Teramukai S, Shimada N, Moriyama M, Hayashi W, et al. Comparison of visual outcome and regression pattern of myopic choroidal neovascularization after intravitreal bevacizumab or after photodynamic therapy. Am J Ophthalmol. 2009;148(3):396-408.

  65. Wu PC, Chen YJ, Chen CH, Chen YH, Kao ML, Shin SJ, et al. Subthreshold transpupillary thermotherapy in Chinese patients with myopic choroidal neovascularization: 1 and 2 year followup. Clin Exp Ophthalmol. 2008;36(5):443-8.

  66. De Juan E, Machamer R. Vitreous surgery for hemorrhagic and fibrous complications of agerelated macular degeneration. Am J Ophthalmol. 1988;105(1):25-9.

  67. Ruiz Moreno JM, De la Vega Galiana C. Tratamiento quirúrgico de la neovascularización coroidea subfoveolar en el miope magno. Análisis de los resultados. Arch Soc Esp Oftalmol. 2001;76(10):593-8.

  68. Fuijii G, Humayun M, Pieramici D. Initial experience of inferior limited macular trasnlocation for subfoveal choroidal neovascularization resulting for cases other than age-related macular degeneration. Ophthalmol. 2001;131(1):90-100.

  69. Hamelin N, Glacet-Bernard A, Brindeau C. Surgical treatment of subfoveal neovascularization in myopia: macular translocation versus surgical removal. Am J Ophthalmol. 2002;133(4):530-6.

  70. Glacet-Bernard A, Simon P, Hamelin N. Translocation of the macula for management of subfoveal choroidal neovascularization: comparison of results in age-related macular degeneration and degenerative myopia. Am J Ophthalmol. 2001;131(1):78-89.

  71. Glacet-Bernard A, Benyelles N, Dumas S, Haddad WM, Voigt M, Razavi S, et al. Photodynamic therapy vs. limited macular translocation in the management of subfoveal choroidal neovascularization in pathologic myopia: a two-year study. Am J Ophthalmol. 2007;143(1):68-76.




2020     |     www.medigraphic.com